

Index

a

- AAD-1566. *See* monepantel
 AAD sensitivity 289, 294
 abamectin 238, 239, 285, 302, 305
 ABCG2 transporter 245
 ABC transport proteins 33
 abomasum 294, 303, 409
Acanthocheilonema viteae jird model 378
 ACC-1. *See* acetylcholine-gated chloride channel
 acetylcholine (ACh) 4, 234, 237, 293
 acetylcholine-gated chloride channel 8, 11, 12
 AC2 gene 28
 acoelomate 106, 423
Acrobes 26
 activation-associated secreted protein (ASP) 409
 adjuvants block copolymer (BC) 387
 adult worm motility (AWM) assays 141
 albendazole 185, 192, 220, 222, 241, 255, 268, 273, 276, 358, 364, 380, 499
 Alhydrogel® 429
 alternatively activated macrophages (AAMFs) 475
 aluminum hydroxide 428
 amidantel 206
 amino-acetonitrile derivatives (AADs) 4, 32, 137, 234, 283
 – biological target of 286
 – chemical structure of 284
 – mis-splicing mutations 292
 γ-aminobutyric acid (GABA) 4
 aminolevulinic acid dehydratase (ALAD) 260
 aminopeptidase 412
 4-aminopiperidine 149
 aminotransferase (AST) 470
 amoscanate 243
Ancylostoma caninum 34, 46, 243, 365, 401
Ancylostoma ceylanicum 271, 349
Ancylostoma duodenale 25, 46, 61, 184, 271, 347, 364
 anthelmintics 3, 234, 421
 – adoption of mechanism-based screens 125
 – agents 24
 – approval, by WHO 268
 – benzimidazole 222
 – chitinase inhibitor/ionophore 241, 242
 – cholinergic agonists 243–245
 – cholinergic antagonists 238
 – compound screening 144
 – Cry protein 269
 – drug discovery (*See also* drug development process)
 – GABA agonist 240
 – gene carrying resistance 244
 – glutamate-gated chloride ion channels (GluClS) 239, 240
 – on hydatid disease in animals 499
 – innate immune response inhibitor 242
 – isothiocyanate-ATP inhibition 243
 – mechanism-based screens for 126
 – modes of action 234, 235
 – AADs (monepantel) 237, 238
 – cholinergic agonists 234–237
 – optimization 148–152
 – pharmacokinetics 211
 – postinfection and efficacy 192
 – potency of Cry5B 273
 – resistance to 5, 244
 – SH ligand 242
 – SLO-1 potassium channel activator 240
 – target sites 5, 6
 – trematocidal drugs, development 326
 – triclabendazole 452
 – types of 233, 234
 – veterinary 220, 223, 229
 antibody-dependent cellular cytotoxicity (ADCC) 379, 384, 454, 455, 466, 475, 477

- anticancer drugs 125
 - antifilarial therapy
 - anti-*Wolbachia* treatment 252–254
 - doxycycline, indications 254, 255
 - antifilarial vaccine development 377–391
 - animal models 383, 384
 - for lymphatic filariae vaccine studies 384–387
 - for *Onchocerca volvulus* vaccine studies 387, 388
 - using nonhuman parasites in rodents 388
 - antipathology vaccine 382, 383
 - antitransmission vaccine 383
 - bovine onchocerciasis 380, 381
 - comparative vaccine studies 388, 389
 - current status 383
 - feline filariasis 381
 - immunity 378, 379
 - multivalent vaccines 389
 - new vaccine candidates, discovery 389–391
 - panhelminth vaccine 383
 - prophylactic vaccines 382
 - anti-fluke vaccines 74
 - antigen
 - complex 404
 - production and delivery approaches 409
 - antihelminth vaccines, candidates
 - development 367
 - anti-HIV therapy 275
 - anti-L3 vaccine 381
 - antioxidant enzymes, immunolocalization
 - studies 438
 - antioxidants 80
 - vaccines 471
 - antipathology vaccine 382, 383
 - antiprotozoals 327
 - antitransmission vaccine 383
 - anti-*Wolbachia* consortium (A·WOL) 251, 252
 - assay development/screening strategy 256, 257
 - drug regimen refinement 256
 - effective antifilarial therapy 252–254
 - library screening
 - anti-infective 259
 - diversity-based 259
 - registered drug 257, 258
 - target discovery 259–262
 - lipid II biosynthesis 261
 - new chemical entities (NCEs) 259
 - screening strategy 257
 - second-generation 256
 - treatment
 - cost- and time-effective strategy 257
 - stunted *L. sigmodontis* larvae 258
 - aquaporin (Ce-AQP-2) 96
 - Artemisia cina* 233
 - artemisinin 77
 - Ascaridia galli* 25, 33, 141–143
 - Ascaridida 67
 - Ascaris lumbricoides* 233
 - Ascaris suum* 13, 26, 61, 128, 234
 - aspartic protease (APR) 365, 401, 405
 - Aspergillus niger* 128
 - Asu-unc-8* 237
 - Asu-unc-63* 237
 - autoimmune diseases 455
 - automated phenotype analysis 166–168
 - for drug screening against 168
 - avermectins 32, 239, 240
 - avr-15* gene 32
 - avr-14* mutant 33
 - axon terminal 287
 - Aztecs 234
- b**
- Babesia bovis* 107
 - Bacillus thuringiensis* crystal (Cry)
 - proteins 267–276
 - anti-roundworm activity 274
 - for *C. elegans* to resist 275, 276
 - Cry21A protein in mice 273, 274
 - free-living roundworms, intoxicate 270
 - hookworm parasite, *in vitro* and *in vivo* 271–273
 - hypersusceptibility studies 274, 275
 - intoxicate animal-parasitic roundworms *ex vivo* 270, 271
 - intoxicate plant-parasitic roundworms 270
 - mechanism of action 269, 270
 - and nAChR agonists, synergy 275
 - plant-parasitic nematodes feed 270
 - safety of 268, 269
 - single-dose therapy of *H. bakeri* 273
 - therapeutic activity 271
 - 1,3-benzenedioic acid 149
 - benzimidazoles 92
 - benzimidazole-bound $\alpha\beta$ -heterodimers 241
 - benzimidazoles 24, 29, 136, 139, 150, 241, 245, 284, 285, 346, 499
 - bioinformatics, recent developments in 14, 53, 62
 - biological image analysis 162
 - algorithmic approach 173
 - CART algorithm 175
 - image capture 163
 - image segmentation 163–166
 - algorithms for schistosome 168–172
 - for filarial parasites for HTS 172, 173

- parasite tracking 164
- quantitative phenotyping 164, 165, 173–175
- resources 162
- results from classifier using data from videos 175
- tracking algorithm 173–175
- workflow for drug screening 162, 163
- BLAST 47, 63, 288
- bovine abomasum 409
- bovine onchocerciasis 380, 381
- Brugia malayi* 5, 45, 92, 128, 136, 252
 - heat-shock protein 128, 129
 - image segmentation of 172
 - recombinant myosin 384
 - target prioritization, using TDR targets database 54
- Brugia pahangi* 381
- β -tubulin ligands 92, 245
 - benzimidazole resistance 245
- C**
- Caenorhabditis briggsae* 13, 27, 63
- Caenorhabditis elegans* 4, 24, 63, 161, 234, 269, 285, 298, 329, 399
 - acr-23, discovery of 294
 - *ben-1* mutant 29
 - chloride currents in 32
 - cholinergic receptor of 236
 - comparative pharmacology of 30
 - functional genomics using 90, 91
 - genetic screening 289
 - genome encodes 241
 - GluCl genes 240
 - glutamate-gated chloride channels 92
 - gut and secretory system 401
 - high-throughput chemical screening and 203
 - lat-1/lat-2 genes 33
 - levamisole receptor channels 31
 - macrocyclic lactone sensitivity 245
 - mutagenesis screen 240
 - mutants resistant 276
 - orthology-based RNAi phenotype data mapping 50–52
 - OrthoMCL database 50
 - TDR Targets database 51
 - WormBase database 51
 - parasitic nematode genes, expressed in 28
 - PF1022A and emodepside inhibited locomotion of 33
 - as platform
 - for anthelmintic characterization 202, 203
 - for anthelmintic drug discovery 203–205
 - for target discovery 34, 35
 - to resist 275, 276
 - sensitive to thiabendazole 29
 - as tool to understand mode of 31–34
 - vaccine antigens expression 410–412
 - wild-type 275
 - xenobiotics 205–207, 212, 213
 - calcium antagonists 313
 - calcium blockers 314
 - calcium channel hypothesis 313
 - calcium signaling cascade 236, 243
 - calpain 111
 - carcinogens 74
 - cathelicidin-like helminth defense molecule 452, 457–459
 - cathepsin B 478
 - like cysteine protease genes 402
 - vaccine 406
 - cathepsin B2 468
 - advantages 469
 - cathepsins L 468, 469
 - cysteine peptidases 453–455
 - cDNA library 66, 389, 437
 - Cel-ACR-23* receptor 290, 291
 - cell-free protein expression systems 425, 426
 - Cephalobidae 26
 - Ce-PHI-10 96
 - cestode infection
 - in humans and livestock 191
 - hybrid vaccines for 473, 485, 487, 488
 - infection models 189
 - RNAi 113, 332
 - selected compounds in rodent models 192
 - taeniid cestode vaccines 498
 - cestode parasites vaccines 485–500
 - against cestode infections in intermediate hosts 487, 488
 - development, strategy 488, 489
 - existing, effective, recombinant vaccines 489
 - fibronectin type III domains 491, 492
 - host-protective antigens characteristics 489, 490
 - practical application prospects 496–498
 - protective antigens 490
 - oncosphere structure and localization 493–496
 - protective immune responses, evidence for 488
 - stage-specific expression 491
 - vaccination and chemotherapy, combination 498, 499
 - vaccine development in definitive hosts 487
 - chemistry-to-gene screens 14, 15

- chemotherapy 357–369, 436
 – based morbidity control 426
Chenopodium ambrosioides 233, 234
 chitinase 128
 cholangiocarcinoma (CCA) 74
 choline concentration–response curve 290
 cholinergic agonists 235
 cloning vaccine candidates 390
 clonorchiasis 324
Clonorchis sinensis 74, 79, 80, 189, 324
 closantel 241, 242
 cofactor-dependent phosphoglycerate mutase (dPGM) 261
 cofactor-independent PGM (iPGM) 261
 combination vaccines 472, 473
 combinatorial chemistry 125
 commercial vaccine, development 477
 comparative genome analyses 25, 44, 67
 complement-fixing circulating antibodies 489
 complex eukaryotic expression vectors 366
 concomitant immunity 485
Cooperia oncophora 34, 46, 140
 CoPs 348, 349, 354
 – reproducibility 354
 crop protection 24
 Cry21A protein 273
 Cry6A proteins 270
 Cry5B proteins 270, 272, 273
 Cry5B–TBD 275
 Cry proteins 268–271, 274, 275
Cryptosporidium 242
 Cry6 subfamily protein (Cry6A) 270
 current Good Manufacturing Practice (cGMP) 343, 344, 350
 cyclo-octadepsipeptide 33
 cyclooxygenase pathway 242
 Cys-Loop LGIC Complex 4, 5, 15
 – *Drosophila melanogaster* 12
 – eukaryotic 15
 – first crystal structure of 15
 – LGC-44, represent ancestral 12
 – superfamilies of other nematodes 13, 14
 Cys-loop LGIC gene superfamily 13
 Cys-loop superfamily 287
 cysteine peptidase inhibitors 455
 cysteine proteases 330, 365, 406–408, 409
 cysticercosis 106
 cystic hydatidosis 488
 cyst nematodes 35
 cytochalasin D (CyD) 314
 cytochrome P450 (CYP) 329
 cytotoxic drugs 125
 cytotoxicity 152
- d**
daf-16 gene 30
Danio rerio 161
 Database of Essential Genes (DEG) 259
 DEG-3/DES-2 oligomer 293
 2-deoxy-paraherquamide 297, 299
 – animal safety studies, pivotal target 303–305
 – commercialization 305
 – derquantel scale-up 305
 – registration/launch 305
 – mode of action 301, 302
 – PNU-141962, characterization 298–301
 – *in vivo* (Jird)/*in vitro* effects against 300
 depsipeptides 137
 derquantel 206, 238
 – toxicity of 300
 dicarboxylic acid 149
 Dicrocoelidae 74
 diethylcarbamazine 123, 125, 242
 – contraindications 380
 Digenea 73
Diphyllobothrium latum 315
 Diplogasterida 25
Dirofilaria immitis 14, 254, 377
 disrupted phenotype 148
 dithiothreitol (DTT) 408
 DNA
 – damage 74
 – immunization 387
 – microarrays 423
 – sequencing 438
 – vaccination 409
 – vaccines 409, 410, 429
 DNA-directed RNA polymerase 260
 dog heart worm 254
 dominant type 2 immune responses 474
 dopamine 4
 dose-reduction index (DRI) values 275
 dose–response curves 350
 double-stranded RNAi 14
 doxycycline 255, 256
 draft genome sequences 422
Drosophila melanogaster 7, 63, 161
 – Cys-loop LGICs 12
 DrugBank database 260
 drug development process 125, 220
 – chemistry, manufacturing, and controls (CMC) aspect 225, 226
 – clinical trials 226, 227
 – CROs, role of 228
 – discovery of hit molecule against 223, 224
 – drug development program and amendments 229

- funding 228
- nonprofit organizations, role in (*See* product development partnerships (PDPs))
- NTD drug development 228
- preclinical studies 224, 225
- regulatory considerations 227, 228
- stages 223, 224
- drug–pathogen interactions 160
- drug resistance 298, 316
- dual-component vaccine 472
- Dugesia japonica* 313
- dyf* genes 239

e

- Echinococcus granulosus* 46, 191, 441, 471, 485, 486, 487, 490
- Echinococcus multilocularis* 46, 113, 191, 326, 486, 489, 490
- Echinostoma caproni* 189, 191, 192, 327
- egg hatch test (EHT) 138, 139
- egg reduction rates (ERRs) 328
- EG95 vaccine 497, 499, 500
- electroporation 97, 111
- ELT-2 polypeptide 29
- emodepside 33, 137, 240
- endoplasmic reticulum 237, 244
 - degeneration of 241
 - receptor protein 244
- enzyme-linked immunosorbent assay
 - analyses 406
- epitopes 383
 - prediction algorithms 390
- Escherichia coli* 91, 126, 140, 261, 270, 344, 405, 428, 441, 458, 470, 489
- EST and genome sequence data 403
- ethyl methane sulfonate 8
- eukaryotic parasites 485
- EuPathDB 44
- excretory/secretory (ES) products 390, 452, 470
- exogenous proteins 428
- expressed sequence tag (EST) sequences 26, 44, 62
- expression system 410, 411

f

- Fasciola gigantica* 74, 75, 191, 438, 466
- Fasciola hepatica* 74, 189, 191, 241, 327, 436
- Fascioliasis 191, 435–437
- Fasciolidae 74
- fasciolid liver flukes, life cycles 76
- fasciolosis 465
- fatty acid-binding protein (FABP) 436, 437
 - binding of drugs 440

- fecal egg count reduction test 303, 304
- feline filariasis 381
- fenbendazole 24, 136
- fibronectin type III (FnIII) domain 491
- filamentous processes 493
- filarial-infected vectors 378
- filarial nematodes 92, 251–262
 - disease-causing species 252
 - first-stage larvae of 254
 - macrofilaricidal drug for 252
- filariasis
 - automated phenotype analysis for drug 168
 - causing organisms (*See* *Wuchereria bancrofti*)
 - chemotherapy of 128
 - lymphatic 187, 188, 254–256, 262, 360–362, 378–389
- Filarioidea 160
- ftkf-1* gene 29
- flatworms. *See* *Clonorchis sinensis*; *Onchocerca volvulus*
- flubendazole 157, 233, 241
- FMRFamide 129
- food-borne zoonosis 477
- Freund's Complete adjuvant (FCA) 384, 468, 473
- fusion proteins 440, 441

g

- GABA-gated chloride channels 9, 32
- GABA receptor cation channels 11
- Galba truncatula* 452
- gastrointestinal nematode parasites of
 - humans 184
 - disease and impact 184, 186
 - hookworm infection
 - Rockefeller Sanitary Commission for eradication 220
 - and rodent models 186, 187
- gastrointestinal parasites of livestock 61
- GeneDB 44
- gene silencing 14
 - by RNAi 412
- genetic heterogeneity 473
- genetic manipulation tools 424
- gene-to-gene variability 111
- genome-sequencing projects 13
- genomics 14
- genotoxicity 152
- Global Access Strategy 362, 367
- Global Network for Neglected Tropical Disease Control 367
- Globodera rostochiensis* 29
- GluCl genes 8, 240, 245
- GluCl modulators 244, 245

- glutamate-gated chloride channels
(GluCl_s) 4, 32, 92
- γ-glutamyl transferase (GGT) 470
- glutathione *S*-transferase (GST) 361, 384, 408, 437, 439, 466
- glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene 29
- Glycine max* 35
- glycosylphosphatidylinositol (GPI) 492
- gpd* gene 29
- gpd-3* gene 29
- G-protein-coupled receptors (GPCRs) 127, 330, 331
- granulin 79
- green fluorescent protein (GFP) 29, 289
- growth factor receptor-binding protein 2 (GRB2) 79
- h**
- Haemonchus contortus* 25, 26, 61, 90, 124, 136, 143, 237, 271, 283, 291, 399, 403, 404, 411
- cysteine proteases 406–408
- microsomal aminopeptidase from 403, 404
- hamster model 271, 349
- H. bakeri* 272–274
- Hco-acr-8* 237
- Hco-AVR-14* 14
- Hco-deg-2* 237
- Hco-deg-3* 237
- Hco-deg-3H* 244
- Hco-des-2H* 244
- Hco-GGR-3* (dopamine) 14
- Hco-igc-38* 26
- Hco-LGC-55* (tyramine) 14
- Hco-mptl-1* 237, 244, 292
- H. contortus* 13, 14, 28, 29, 33, 34, 64, 91, 96, 97, 126, 140, 144, 184, 237, 243, 244, 284, 291, 294, 402, 403, 406, 411, 412
- *acr-23* 237
- Hco-unc-29.1* 237
- Hco-unc-38* 237
- Hco-unc-63a* 237
- Hco-unc-63b* 243
- healthcare delivery systems 369
- heat-shock protein 128
- neuromuscular targets in 129, 130
- helical wheel analysis 458
- helminth defense molecule (HDM)-1 458
- Hereford calves 471
- Heterodera glycines* 35
- H-gal-GP 404, 405
- high-throughput screening (HTS) 160
- hookworm vaccine
- bioassay for potency 349
- human immune response 347–349
- infection, natural history 347
- NTD vaccines 346, 347, 349–354
- potency assay 344–346
- preclinical development 343–354
- preclinical testing 349
- valley of darkness 350, 351
- host immune effector molecules 390
- host immune responses 426, 459
- host immune system 402
- host–parasite systems 388
- host-protective antigens 490, 494
- host's immune effector cells 456
- H. polygyrus* 273
- H11protein 97
- 5-HT channels 11
- human drug pharmacopeia screen 258
- human ether-a-go-go related gene (hERG) 329
- human hookworm vaccine 369
- PDP strategy 368
- human papilloma virus (HPV) vaccines 368
- hydatid disease 497, 499
- hyperpolarization 240
- hypersusceptibility 275
- i**
- IgE-mediated disorders 349
- IgG antibody 348, 365, 470
- cleavage 402
- IgG4 isotype 454
- Illumina technology 66, 78
- image analysis workflow, for drug screening 162. *See also* biological image analysis
- imidazolides 298
- imidazothiazoles 24, 136, 234
- immobilized metal-affinity chromatography 441
- immune modulation mechanisms 451–460
- immune regulatory networks 379
- immune responses 488
- kinetics 380
- level and type 382
- immunity 378, 379, 473–475
- immunization challenge model 345
- requirements 345
- immunization experiments 440
- immunization protocols 388, 389
- immunoelectron microscopy 469
- immunogold methods 493
- immunolocalization, of Sm14 protein 439

- immunoprophylaxis 437, 465–478
 individual drug administration (IDA) 255
 – current recommended treatment strategies for 253
 Indonesian thin tail (ITT) 466
 inflammatory bowel disease (IBD) 459
 innovative developing countries (IDCs) 367
 interferon (IFN)- γ 473
 intestinal fluke infections 324
 intestinal schistosomiasis 422
 intracellular protein 438
 investigational new drug (IND) 327
in vivo biological assays 351
in vivo RNAi, development 410
 iron deficiency anemia (IDA) 347
 ivermectin 7, 15, 24, 137, 297
 – *Hcavr-14* (*HcGluCla3*), involved in 33
 – to nematode Cys-loop LGICs 15
 – resistance 360
 – sensitivity in *C. elegans* 7
 – triple mutant, *avr-14/avr-15/glc-1*, resistant to 32
 – use in onchocerciasis 359
- k**
 Kato–Katz diagnostic technique 310
 KCNMA1 gene 34
- l**
 LAP vaccine 469–471
 larval development assay (LDA) 283
 larval migration inhibition test (LMIT) 139
 larval paralysis test (LPT) 140
 laser microdissection microscopy (LMM) 423
 latrophilin receptor (*lat-2*) 33, 240
Leishmania major 107
 leucine amino peptidase (LAP) vaccine 401, 466, 469–471
lev-1 236
lev-8 236
lev-9 237
lev-10 237
LEV-11 15, 236, 243
 levamisole 8, 24, 31, 136, 236, 237, 285
 – resistance 236, 243, 244
 – targets 288
 levamisole receptors 31, 236, 243
 – *UNC-22* 15, 236
 – *unc-29* 236, 243
 – *unc-38* 236, 243
 – *unc-50* 237
 – *unc-63* 236, 243
 – *UNC-68* 15, 236, 243
 – *unc-74* 237
- levant wormseed 233
 L-glutamate 7
 ligand-gated anion channels 7, 26
 – LGC-32 12
 – LGC-33 12
 – LGC-34 12, 14
 – LGC-35 11
 – LGC-40 12
 – LGC-42 12
 – LGC-45 12
 – LGC-50 11
 – LGC-53 12
 lipooxygenase 242
 lipophilicity 151
 lipopolysaccharide (LPS) 454
 lipoproteins 261
 liquid chromatography-tandem mass spectrometry 424
Litomosoides carinii 188
Litomosoides sigmodontis 255, 383
 liver flukes 73, 74, 324, 451. *See also Fasciola hepatica*; fasciolosis
 – life cycles 76
 – omics research of 79–81
 – signs and pathological changes associated with 75
 – socioeconomic importance 75
 – transcriptomic studies 77–79
 – resources 79
 L3 surface-specific antibodies 379
 lung fluke. *See Paragonimus westermani*
Lymnaea stagnalis 12
Lymnaea truncatula 452
 lymphatic filariasis 187, 188, 256, 360–362, 378, 382
 – natural host–parasite systems 380
 – vaccine 361, 385, 386
- m**
 macrocyclic lactones 24, 136, 137, 239, 244
 macrofilaricidal activity 254
 macrophages 456, 459
 – endosomes 460
 – populations characteristics 457
 Malachite Green 128
Manduca sexta 161
Mansonella perstans 254
 marcfortine A 298, 299
 marcfortine G ring 298
 mass drug administration (MDA) 186, 221, 251, 357, 358, 361, 369, 377, 380, 382, 391, 421
 – strategies for 253
 mebendazole 241

- median effective dose (ED₅₀) method 351
 mefloquine 328, 329
 meiosis 285
 melarsamine 242
Meloidogyne arenaria 25, 26
Meriones unguiculatus 283
 MEROPS peptidase database 470
 metacercariae vaccine 472
 metacestodes 494
 micro agar larval development test (MALDT) 140
 microarray analysis 44
 microfilariae 378
 microfilaricidal drugs 254
 microtubules 92, 241
 miracidium 107
 MOD-1 (modulation of locomotion defective) 11
 modified T_H2 response 347, 348
 monepantel 137, 283–294
 – acetylcholine receptors 294
 – ACR-23 channel modulator 291
 – amino-acetonitrile derivatives, discovery of 283, 284
 – commercial formulation 284
 – efficacy of 284, 285
 – hypothetical interaction 294
 – interference, hypothetical model of 293
 – mode of action 285–288
 -- *Cel*-ACR-23 receptor, functional characterization 290, 291
 -- *C. elegans*, use of 289
 -- *H. contortus* monepantel-1 gene, discovery 291–293
 -- model for 294
 – molecular mechanism 291
 – optical *R*-enantiomer 291
 – resistance 244
 – selection of 284, 285
 – tolerability of 285
 monophosphoril lipid A (MPL) 441
 motility tests 141
 moxidectin 245
mptl-1 gene 244
 multivalent cathepsin vaccine 469
 multivalent vaccines 389, 391, 473
 – approach 389
 – cathepsin vaccine 389
 murine model systems 473
Mus musculus 63, 161
 mutation 91, 92
 – in the β -tubulin isotype I 245
 – of genes required for *C. elegans* cuticle integrity 212
 – of GluCl α 1–3 8
 – *tub-1* gene 29
Mycobacterium fortuitum 441
- n**
- nAChR agonists 274
 – anti-roundworm activity 274
 – Cry Proteins, synergy 275
 – hypersusceptibility studies 274, 275
 nAChR gene families 8, 9
N-acyl amino-acetonitriles 283
 national immunization programs 368
 native proteins
 – protective effects 413
 – vaccine, impact 407
Necator americanus 13, 25, 46, 61, 62, 346, 364
 neglected tropical disease (NTD)
 vaccines 159, 219, 220, 343, 350, 351, 354
 – adverse consequences 366
 – candidate antigens, discovery 343
 – cautionary tale for 346, 347
 – challenge for 344
 – potency assays 350, 351–354
 – potency testing for 349, 350
 Nematoda 127
 nematode-induced immune regulatory system 379
 nematode infection models 182
 – *Haemonchus* rodent models 183, 184
 – nematode infections in livestock 182, 183
 – other nematode species for 184
 -- efficacious doses of selected compounds against 185, 186
 – *Trichostrongylus* rodent models 183
 nematode infections in livestock 182, 183
 nematode screening, *in vitro* 256
 nematode-specific nAChRs 11
Nematospiroides dubius 273
 neurocysticercosis 497, 500
 neuron-specific antibodies 289
 neurotransmitter-gated ion channels 286
 neurotransmitters 12
 newly excysted juveniles (NEJs) 467
 new vaccine candidates, discovery 389–391
 NGS datasets 63
 nicardipine 313, 314
 nickel chelation chromatography 411
 nicotinic acetylcholine receptors (nAChRs) 26, 286, 301
 – agonists 268
 – DEG-3 subfamily 288
 – homopentameric 235
 – N-, L-, and B-subtypes of 301
 – types of 301

- nifedipine 313
Nippostrongylus brasiliensis 25, 92, 271
 nitazoxanide 242, 243, 268
 4-nitrophenylpiperidine 149
 nitroscanate 243
 nonhomologous isofunctional enzymes (NISEs) 261
 nonhuman test systems 343
 nontaniid proteins 492
 N-type nAChRs 11
- o**
- Oesophagostomum dentatum* 13, 144, 243
 – anthelmintic bioassays 146
 off-gel electrophoresis technique 424
oig-4 237
Onchocerca gutturosa 257, 259
Onchocerca volvulus 28, 45, 91, 92, 128, 136, 188, 189, 241, 252, 254, 359, 360, 361, 379, 381, 383, 387, 388, 389, 390
 – cellular immune response to 379
 – vaccine candidates 385, 386
 –– *Ov*-CPI-2 (*Ov*7) 381
 onchocerciasis 188, 255, 256
 – control programs 359
 – ivermectin use 359
 – natural host–parasite systems 380
 oogenesis 254
 open reading frames (ORFs) 63
 opisthorchiasis 324
 Opisthorchiidae 74
 opisthorchiid flukes. *See* *Opisthorchis viverrini*
Opisthorchis viverrini 74, 324, 327
 ornithine decarboxylase (ODC) 126
Ostertagia circumcincta 28, 271
Ostertagia ostertagi 25, 61, 96, 300, 399, 407
 – cysteine proteases 409
Ov-GST-3 gene 29
 oxibendazole 241
- p**
- p*-amino-phenethyl-*m*-trifluoromethylphenyl piperazine (PAPP) 129
Panagrellus redivivus 270
 panhelminthic vaccines 383
 paragonimiasis 324
Paragonimus westermani 189, 315
 paraherquamide 92, 298, 299
 parasite antigens 459
 parasite defense proteins 475
 parasite tracking 174
 parasitic helminths
 – genome sequence information 45, 46
 – orthology-based RNAi phenotype data mapping 50–52
 – unavailable genomic datasets 55, 56
 –– targeted gene disruptions 55
 parasitic nematode neurotransmitter receptors 30
 parasitic nematodes 25, 61, 240
 parasitic worms 233
 penetration gland
 – type 1 (PG1) 493
 – type 2 (PG2) 493
Penicillium simplicissimum 297
pep-1 gene 28
 peptides, annotation of 66
 – public databases 66
 peroxidic compounds 478
 peroxiredoxin 112, 455–457, 471, 472
 – activated macrophages 457
 – protein expression 456
 – specific antibodies
 –– administration 457
 PF1022A 33
 P-glycoproteins 33, 239
 phenothiazine 238
 phenylacetylglycine (PAG) 333
 phosphoenolpyruvate carboxykinase (PEPCK) 126
 phosphofructokinase (PFK) 126
 phylogenomics 14
 physiology-based assays 138, 139
 – on L3 and adult helminths 140, 141
 – on nematode
 –– egg hatch test (EHT) 139
 –– larval development test (LDT) 140
 – screening, using parasitic nematode stages 141–144
 picrotoxin 5
 piperazine 235, 240
 – targets for 9–11
Plasmodium falciparum 107
 Platyhelminthes 106
 PNU-141962. *See* 2-deoxy-paraherquamide
 PNU-105775, synthesis 298
 polar surface area (PSA) 149
 polymerase chain reaction (PCR) 289, 387
 porcine vaccine 366
 pore-forming toxins (PFTs) 270
 potency assays 344–346
 potency testing program 344, 352, 353
 praziquantel (PZQ) 74, 309–316, 362
 – chemotherapy 310
 – cure rates (CRs) 324

- inositol phosphates 315
 - juvenile worms 311
 - limitations 310
 - mass distribution 311
 - mechanism of action 312–315
 - paragonimiasis therapy 324
 - performance improvement 315, 316
 - resistance 311, 312
 - schistosomiasis 315
 - therapeutic success 325
 - upstream 313
 - Pristionchus pacificus* 26, 32, 270
 - product development partnerships (PDP) 219, 220, 228, 363
 - proinflammatory cytokines 380
 - prolactin receptors 492
 - prophylactic vaccines 382
 - protective adaptive immune responses
 - development 451
 - protective immune response 350
 - protective oncosphere antigens 491
 - protein abundance index score 476
 - protein arrays 390
 - protein-coding expressed sequence tags (ESTs) 402
 - Protein Data Bank 55, 56
 - protein kinase C (PKC) signaling pathways 240
 - proteolytic enzymes 423
 - proteomics 44
 - proton ionophore effect 242
 - putative ligand-gated ion channel genes
 - phylogenetic tree 288
 - pyrantel 24, 237
 - resistance 243, 244
 - pyrazino isoquinoline ring system 310
 - pyruvate phosphate dikinase (PPDK) 261
- q**
- quantitative polymerase chain reaction (qPCR) 256
- r**
- rapid nutrient turnover 401
 - Ras-related C3 botulinum toxin substrate 1 (RAC1) 79
 - rational drug design (RDD) 326
 - reactive oxygen species (ROS) 80, 455
 - rebound morbidity 362
 - recombinant nematode proteases production 410
 - recombinant proteins 381, 473, 489
 - revitalizing concept 357
 - Rhabditida 25
 - ric-3* 237
 - rifampicin 255, 256
 - RNA interference (RNAi) 35, 44, 67, 91, 326, 363, 412, 413, 423, 425, 429
 - calcium channel β -subunit 314
 - as discovery tool 110–112
 - drugs, based on 113
 - gene silencing 412
 - induced phenotypes and identifying essential genes 112
 - lead to, suppression of genes 110
 - in other parasitic platyhelminths 113, 114
 - in parasitic nematodes 92–96
 - improving 97, 98
 - in platyhelminths 106
 - in Schistosomes 108, 109
 - pathway 109, 110
 - *in vivo* 96, 97
 - Rockefeller Sanitary Commission 220
 - rodent models
 - for developments of anthelmintics 181
 - *Haemonchus* rodent models 183, 184
 - important translation step 182
 - of lymphatic filarial infection 188
 - of Onchocerciasis 189
 - of other STH infections 187
 - for schistosome infection 189, 191
 - for *Strongyloides stercoralis* 187
 - *Trichostrongylus* rodent models 183
 - roundworms. *See* Ascaris
- s**
- Sabin Vaccine Institute 426
 - Saccharomyces cerevisiae* 63, 107, 126
 - Sanger sequencing 63
 - Schistosoma* 106
 - Schistosoma haematobium* 11, 189, 312, 327, 362, 363
 - Schistosoma japonicum* 77
 - vaccine, advantage 364
 - Schistosoma mansoni* 45, 77, 92, 107, 161, 189, 311
 - activity of selected compounds 192
 - fatty acid-binding protein 435, 436
 - genome information 331
 - increased sepsis following infection 458
 - infection 333
 - inhibitors of thioredoxin glutathione reductase in 92
 - mouse model 329, 333
 - purine nucleoside phosphorylase in 126
 - *Sm28-GST* and *Sh28-GST* 362
 - suppression of genes in 110

- target prioritization, using TDR Targets Database 54, 55
 - tegumental surface tetraspanin (Sm-TSP-2) 363
 - tegument, fluorescence micrograph 428
 - schistosomes 55, 330
 - drug sensitivity 312
 - gene suppression in 109
 - genome sequences 330
 - genomics, and transcriptomics 422, 423
 - helper T cell T_h2 responses 348
 - immunomics 425, 426
 - postgenomics 424, 425
 - proteomics 423, 424
 - protocol for RNAi in 332
 - quantitative whole-organism screens for 161
 - RNAi in 108, 109
 - pathway 109, 110
 - *Sm-tsp-2* transcript fail to generate 363
 - TGR and peroxiredoxin for 112
 - transient RNAi and its application in 111, 112
 - transmitted through 423
 - schistosomiasis vaccines 106, 362–364, 421–430, 435–437, 445
 - antigens ranking table for 427
 - automated phenotype analysis for drug screening 168
 - cases for 426
 - schistosomes 422
 - genomics and transcriptomics 422, 423
 - immunomics 425, 426
 - postgenomics 424, 425
 - proteomics 423, 424
 - Sm-TSP-2 vaccine 426–429
 - Schmidtea mediterranea* 107
 - secreted cysteine proteases
 - as vaccines 467–469
 - secretory blebs 490
 - secretory signals 492
 - Sequence Read Archive (SRA) 63
 - serotonin receptor, screen for ligands 129
 - sex chromosome 422
 - Sigmodon hispidus* 188
 - signal-to-noise ratio 165
 - silence schistosome genes 425
 - slo-1* mutants 34
 - small interfering RNA (siRNA) 97
 - small-scale vaccine programs 497
 - SmAP gene 111
 - Sm14-M20V62 protein 443
 - process of purification 444
 - solution structure, by NMR 443
 - smoke-screen 476
 - Sm14 protein stability 442, 443
 - Sm-TSP-2 vaccine 429
 - Sm14 vaccine antigen, discovery 437, 438
 - soil transmitted helminthiases (STHs) 61, 220, 267, 357, 364, 435
 - spiroindole (2-desoxyparaherquamide) 238
 - Spirurida 67
 - sporocyst 107
 - SPRM1hc gene 111
 - Startect 302, 303–305
 - Stilbamidine 127
 - Strongylida 25, 67
 - Strongyloides ratti* 32
 - Strongyloides stercoralis* 25, 29, 187, 205
 - rodent models 187
 - structure–activity relationship (SAR) models 161
 - superoxide radicals 466
 - surface tegument proteins, as candidate vaccines 475–477
 - S581Y 245
- t**
- Taenia ovis* 486, 489, 490
 - confocal immunofluorescence images 495
 - oncosphere schematic diagram 494
 - vaccine development program 496
 - Taenia solium* 313, 485, 486
 - confocal immunofluorescence images 495
 - control measures 498
 - metacestode 410
 - Taenia taeniaeformis* 486, 488
 - taeniid cestode
 - definitive hosts 487
 - protective antigens 490
 - recombinant oncosphere antigens 490
 - vaccines 489
 - tapeworms. *See* cestodes
 - target product profile (TPP) 221–223
 - target protein 413
 - tct-1* gene 30
 - TDR Targets Database 52–54
 - strategies employed to prioritize targets using 53
 - tegument-associated proteins 476, 496
 - Teladorsagia circumcincta* 13, 237, 301
 - impact 400
 - scanning electron micrograph 400
 - Teladorsagia trifurcata* 303
 - tetrahydropyrimidines 24
 - T_h1-associated phenotype 455
 - T_h2-driven immune responses 387, 452

- Therapeutics for Rare and Neglected Diseases (TRND) program 328
- thiabendazole 241
- thiol-Sepharose-binding proteins (TSBPs) 407
- protein components 408
- thioredoxin glutathione reductase 92, 112, 127, 329, 471
- thioredoxin reductase 471
- thiourea 243
- T_H2/T_{reg}-mediated immune environment 451
- T_H1-type immune responses 478
- toll-like receptor (TLR) 4 454
- Torpedo marmorata* 7
- toxin neutralization 344
- transcriptomes 62
- of parasitic nematodes 67
- of strongylid nematodes 63–65
- transcriptome sequencing projects 413
- transferrin 98
- transforming growth factor (TGF)- β 452
- transient RNAi 332
- translational science 182
- transmission-blocking veterinary product 364
- T regulatory cells 379
- trematocidal drugs 326
- Trematoda 73
- trematodes 55
- infections in humans and livestock 189
- parasites 4
- trematodiasis 323
- challenges confronting drug discovery for 325, 326
- current therapy 324, 325
- disability-adjusted life years (DALYs) 324
- food-borne 324
- genomics tools 330–332
- metabolic profiling 332, 333
- phenotypic screening 329, 330
- reinvigorated trematode drug discovery 326–328
- repurposing drugs 328, 329
- schistosomiasis 323
- target validation through reverse genetics 332
- tribendimidine (TBD) 77, 268
- Trichostrongylus colubriformis* 92, 271, 283
- Trichuris trichiura* 61, 268
- triclabendazole (TCBZ) 74, 324, 325, 439, 466, 477
- resistance 467
- Trypanosoma cruzi* 107
- TSOL18 vaccine 498, 499, 500
- tub-1(iSE)* gene 29
- tubulin-binding genes 245
- tumor-associated inflammation 456
- tumor necrosis factor (TNF)- α 454
- Tylenchida* 26
- tyramine 4
- U**
- UniGene 63
- US Code of Federal Regulations (CFRs), for potency testing 345
- US Food and Drug Administration (FDA) 223, 260, 327, 350
- V**
- vaccination-plus-oxfendazole treatment 499
- vaccines
- antigens 424
- product development strategies 366–368, 377
- vaccinology 381, 382
- vermifuges 234
- verticilliprone 128
- Voronoi tessellation 166
- W**
- Western blot analysis 409
- whole organism in culture strategy 124
- Wolbachia* bacterial endosymbionts 251–262
- Wolbachia* depletion 254
- World Health Assembly resolution 368
- World Health Organization (WHO) 44, 358, 367, 378, 435, 465, 478
- Training in Tropical Diseases (TDR) 436, 442
- WormBase 14
- worm therapy 459
- Wuchereria bancrofti* 45, 50, 136, 252, 361, 377
- X**
- xenobiotic resistance, circumventing 207
- modifying chemistry 208–212
- modifying screening paradigm 207, 208
- xenobiotics 205–207, 212, 213
- Xenopus laevis* 32
- Xenopus* oocytes 236, 237, 243, 290, 313
- expression 237
- xL3-vaccine model 387
- Z**
- Zeldia* 26
- Zolvix 90